In vivo nano-biosensing element of red blood cell-mediated delivery

Ruixue Zhu; Tatiana Avsievich; Alexey Popov; Alexander Bykov; Igor Meglinski

doi:10.1016/j.bios.2020.112845

In vivo nano-biosensing element of red blood cell-mediated delivery

Ruixue Zhu, Tatiana Avsievich, Alexey Popov, Alexander Bykov, Igor Meglinski^*

^*Corresponding author for this work

Mechanical, Biomedical & Design Engineering

Research output: Contribution to journal › Review article › peer-review

Abstract

Biosensors based on nanotechnology are developing rapidly and are widely applied in many fields including biomedicine, environmental monitoring, national defense and analytical chemistry, and have achieved vital positions in these fields. Novel nano-materials are intensively developed and manufactured for potential biosensing and theranostic applications while lacking comprehensive assessment of their potential health risks. The integration of diagnostic in vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous potential in next-generation theranostic platforms. Controllable, precise, and safe delivery of diagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cells is an important determinant in developing advanced nanobiosensor-based theranostic platforms. Particularly, inspired by the comprehensive biological investigations on the red blood cells (RBCs), advanced strategies of RBC-mediated in vivo delivery have been developed rapidly and are currently in different stages of transforming from research and design to pre-clinical and clinical investigations. In this review, the RBC-mediated delivery of in vivo nanobiosensors for applications of bio-imaging at the single-cell level, advanced medical diagnostics, and analytical detection of biomolecules and cellular activities are presented. A comprehensive perspective of the technical framework of the state-of-the-art RBC-mediated delivery systems is explained in detail to inspire the design and implementation of advanced nanobiosensor-based theranostic platforms taking advantage of RBC-delivery modalities.

Original language	English
Article number	112845
Journal	Biosensors and Bioelectronics
Volume	175
Early online date	24 Nov 2020
DOIs	https://doi.org/10.1016/j.bios.2020.112845
Publication status	Published - 1 Mar 2021

Bibliographical note

Funding Information:
This work was partially funded by the China Scholarship Council ( CSC No. 201706410089, R.Z. ), STSM Grant from COST Action CA 17,140 ″Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology) (grant No. ECOST-STSM-CA17140-230,919-113049, R.Z. ). EDUFI Fellowship ( TM-17-10,370, TM-18-10,820, T.A. ) and Suomen Kulttuurirahasto (grant No. 00190188, T.A. ). The authors also acknowledge the contribution of Russian Science Foundation (Projects: 19-72-30012 and 20-64-46003 ). I.M. acknowledges partial support from the Academy of Finland (project 325,097 ), MEPhI Academic Excellence Project (Contract No. 02. a03.21.0005 ) and the National Research Tomsk State University Academic D.I. Mendeleev Fund Program .

Publisher Copyright:
© 2020

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

Drug delivery
Mediated delivery
Nano-biosensing
Nano-biosensor
Nanoparticles
Red blood cells

Access to Document

10.1016/j.bios.2020.112845

Cite this

@article{adc068534e984f9db451e48e2f587a9f,

title = "In vivo nano-biosensing element of red blood cell-mediated delivery",

abstract = "Biosensors based on nanotechnology are developing rapidly and are widely applied in many fields including biomedicine, environmental monitoring, national defense and analytical chemistry, and have achieved vital positions in these fields. Novel nano-materials are intensively developed and manufactured for potential biosensing and theranostic applications while lacking comprehensive assessment of their potential health risks. The integration of diagnostic in vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous potential in next-generation theranostic platforms. Controllable, precise, and safe delivery of diagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cells is an important determinant in developing advanced nanobiosensor-based theranostic platforms. Particularly, inspired by the comprehensive biological investigations on the red blood cells (RBCs), advanced strategies of RBC-mediated in vivo delivery have been developed rapidly and are currently in different stages of transforming from research and design to pre-clinical and clinical investigations. In this review, the RBC-mediated delivery of in vivo nanobiosensors for applications of bio-imaging at the single-cell level, advanced medical diagnostics, and analytical detection of biomolecules and cellular activities are presented. A comprehensive perspective of the technical framework of the state-of-the-art RBC-mediated delivery systems is explained in detail to inspire the design and implementation of advanced nanobiosensor-based theranostic platforms taking advantage of RBC-delivery modalities.",

keywords = "Drug delivery, Mediated delivery, Nano-biosensing, Nano-biosensor, Nanoparticles, Red blood cells",

author = "Ruixue Zhu and Tatiana Avsievich and Alexey Popov and Alexander Bykov and Igor Meglinski",

note = "Funding Information: This work was partially funded by the China Scholarship Council ( CSC No. 201706410089, R.Z. ), STSM Grant from COST Action CA 17,140 ″Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology) (grant No. ECOST-STSM-CA17140-230,919-113049, R.Z. ). EDUFI Fellowship ( TM-17-10,370, TM-18-10,820, T.A. ) and Suomen Kulttuurirahasto (grant No. 00190188, T.A. ). The authors also acknowledge the contribution of Russian Science Foundation (Projects: 19-72-30012 and 20-64-46003 ). I.M. acknowledges partial support from the Academy of Finland (project 325,097 ), MEPhI Academic Excellence Project (Contract No. 02. a03.21.0005 ) and the National Research Tomsk State University Academic D.I. Mendeleev Fund Program . Publisher Copyright: {\textcopyright} 2020 Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.bios.2020.112845",

language = "English",

volume = "175",

journal = "Biosensors and Bioelectronics",

issn = "0956-5663",

publisher = "Elsevier",

}

TY - JOUR

T1 - In vivo nano-biosensing element of red blood cell-mediated delivery

AU - Zhu, Ruixue

AU - Avsievich, Tatiana

AU - Popov, Alexey

AU - Bykov, Alexander

AU - Meglinski, Igor

N1 - Funding Information: This work was partially funded by the China Scholarship Council ( CSC No. 201706410089, R.Z. ), STSM Grant from COST Action CA 17,140 ″Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology) (grant No. ECOST-STSM-CA17140-230,919-113049, R.Z. ). EDUFI Fellowship ( TM-17-10,370, TM-18-10,820, T.A. ) and Suomen Kulttuurirahasto (grant No. 00190188, T.A. ). The authors also acknowledge the contribution of Russian Science Foundation (Projects: 19-72-30012 and 20-64-46003 ). I.M. acknowledges partial support from the Academy of Finland (project 325,097 ), MEPhI Academic Excellence Project (Contract No. 02. a03.21.0005 ) and the National Research Tomsk State University Academic D.I. Mendeleev Fund Program . Publisher Copyright: © 2020 Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Biosensors based on nanotechnology are developing rapidly and are widely applied in many fields including biomedicine, environmental monitoring, national defense and analytical chemistry, and have achieved vital positions in these fields. Novel nano-materials are intensively developed and manufactured for potential biosensing and theranostic applications while lacking comprehensive assessment of their potential health risks. The integration of diagnostic in vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous potential in next-generation theranostic platforms. Controllable, precise, and safe delivery of diagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cells is an important determinant in developing advanced nanobiosensor-based theranostic platforms. Particularly, inspired by the comprehensive biological investigations on the red blood cells (RBCs), advanced strategies of RBC-mediated in vivo delivery have been developed rapidly and are currently in different stages of transforming from research and design to pre-clinical and clinical investigations. In this review, the RBC-mediated delivery of in vivo nanobiosensors for applications of bio-imaging at the single-cell level, advanced medical diagnostics, and analytical detection of biomolecules and cellular activities are presented. A comprehensive perspective of the technical framework of the state-of-the-art RBC-mediated delivery systems is explained in detail to inspire the design and implementation of advanced nanobiosensor-based theranostic platforms taking advantage of RBC-delivery modalities.

AB - Biosensors based on nanotechnology are developing rapidly and are widely applied in many fields including biomedicine, environmental monitoring, national defense and analytical chemistry, and have achieved vital positions in these fields. Novel nano-materials are intensively developed and manufactured for potential biosensing and theranostic applications while lacking comprehensive assessment of their potential health risks. The integration of diagnostic in vivo biosensors and the DDSs for delivery of therapeutic drugs holds an enormous potential in next-generation theranostic platforms. Controllable, precise, and safe delivery of diagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cells is an important determinant in developing advanced nanobiosensor-based theranostic platforms. Particularly, inspired by the comprehensive biological investigations on the red blood cells (RBCs), advanced strategies of RBC-mediated in vivo delivery have been developed rapidly and are currently in different stages of transforming from research and design to pre-clinical and clinical investigations. In this review, the RBC-mediated delivery of in vivo nanobiosensors for applications of bio-imaging at the single-cell level, advanced medical diagnostics, and analytical detection of biomolecules and cellular activities are presented. A comprehensive perspective of the technical framework of the state-of-the-art RBC-mediated delivery systems is explained in detail to inspire the design and implementation of advanced nanobiosensor-based theranostic platforms taking advantage of RBC-delivery modalities.

KW - Drug delivery

KW - Mediated delivery

KW - Nano-biosensing

KW - Nano-biosensor

KW - Nanoparticles

KW - Red blood cells

UR - http://www.scopus.com/inward/record.url?scp=85097067027&partnerID=8YFLogxK

UR - https://www.sciencedirect.com/science/article/pii/S0956566320308319?via%3Dihub

U2 - 10.1016/j.bios.2020.112845

DO - 10.1016/j.bios.2020.112845

M3 - Review article

C2 - 33262059

AN - SCOPUS:85097067027

SN - 0956-5663

VL - 175

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

M1 - 112845

ER -

In vivo nano-biosensing element of red blood cell-mediated delivery

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this